”Hey, there’s this novel product that I tried when faced with a hopeless situation and it turned out to be pretty good and beating my expectations. You might want to give it a try too.”
Then we had:
”There’s this novel product that’s been shown to work extremely well in bad burns cases and I gave it a try in a complex wound situation and the results were impressive.”
Eventually came:
“BTM has a strong track record of use in X, Y, and Z type cases with established protocols for use as the standard of care. So, we thought that we’d try it out in A, B, and C cases where dermal substitutes have not been used before now. This has met with success and we encourage you to consider doing the same.”
And not a dud evaluation amongst the lot.
I look forward to reading the many papers yet to be written on the further extensions of use for BTM but also what is now being made possible with its offshoot MTX.
PNV Price at posting:
$2.03 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)